Tirzepatide vs Semaglutide
Tirzepatide vs semaglutide: these are two different medicines, each sold under more than one brand.
Paste this code into your page. It shows the GLP-1 comparison chart with one plain credit link.
Learn
More about this page
Tirzepatide is in Mounjaro and Zepbound. Semaglutide is in Ozempic, Wegovy and Rybelsus. This page puts their FDA labels side by side, brand by brand.
The main difference in the labels
The labels describe each medicine by the receptors it acts on. GLP-1 is a gut hormone that helps control blood sugar and food intake, a 2018 review explains. GIP is another hormone the body makes.
- Tirzepatide: the labels call it a GIP receptor and GLP-1 receptor agonist. It acts on two hormone receptors.
- Semaglutide: the labels call it a GLP-1 receptor agonist. It acts on one.
Both come as a once weekly shot. Semaglutide also comes as a once daily tablet. The current tirzepatide labels list shots only. For more on how each one acts, see how do GLP-1 drugs work.
Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.
Mounjaro vs Ozempic
These two labels are both about adults with type 2 diabetes. Mounjaro's label also reaches children aged 10 and up, for blood sugar control.
| Label fact | Mounjaro | Ozempic |
|---|---|---|
| Medicine (molecule) | tirzepatide | semaglutide |
| Type | GIP and GLP-1MOUNJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist | GLP-1OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist |
| Maker on the label | Eli Lilly and Company | Novo Nordisk Pharmaceutical Industries, LP |
| Taken as | Injection: pen or vial pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens | Injection: pen or prefilled syringe single-patient-use pens ... single-dose prefilled syringe |
| How often, per label | Once weekly Administer MOUNJARO once weekly, any time of day, with or without meals. | Once weekly Administer OZEMPIC once weekly, on the same day each week |
| Approved uses, per label (names only) |
|
|
| Boxed warning | Yes WARNING: RISK OF THYROID C-CELL TUMORS | Yes WARNING: RISK OF THYROID C-CELL TUMORS |
| Label read | Mounjaro label, version 40, effective August 27, 2026 | Ozempic label, version 20, effective June 1, 2026 |
| FDA approval record | NDA215866, first approved May 13, 2022 | NDA209637, first approved December 5, 2017 |
Wegovy vs Zepbound
Both labels list excess body weight as a use. Their other uses differ. Wegovy's label also lists cardiovascular risk, and MASH for the shot only. Zepbound's label also lists sleep apnea.
| Label fact | Wegovy | Zepbound |
|---|---|---|
| Medicine (molecule) | semaglutide | tirzepatide |
| Type | GLP-1WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist | GIP and GLP-1ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist |
| Maker on the label | Novo Nordisk Pharmaceutical Industries, LP | Eli Lilly and Company |
| Taken as | Injection: pen single-patient-use pen (WEGOVY FlexTouch) Tablet: tablet Take one WEGOVY tablet orally | Injection: pen or vial pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens |
| How often, per label | Once weekly (injection) Administer WEGOVY injection once weekly, on the same day each week Once daily (tablet) Take one WEGOVY tablet orally once daily | Once weekly Administer ZEPBOUND once weekly at any time of day, with or without meals. |
| Approved uses, per label (names only) |
|
|
| Boxed warning | Yes WARNING: RISK OF THYROID C-CELL TUMORS | Yes WARNING: RISK OF THYROID C-CELL TUMORS |
| Label read | Wegovy label, version 19, effective June 18, 2026 | Zepbound label, version 40, effective August 28, 2026 |
| FDA approval record | NDA215256, first approved June 4, 2021 NDA218316, first approved December 22, 2025 | NDA217806, first approved November 8, 2023 |
These two tables name each approved use in short. The label's exact words for every use are on the Ozempic vs Wegovy and Mounjaro vs Zepbound pages.
The head to head trial
One trial compared the two medicines directly, in adults with obesity. Here is how its own abstract describes it, with a link to the paper.
| Trial | DOI 10.1056/NEJMoa2416394 |
|---|---|
| Design, as the abstract states it | phase 3b, open-label, controlled trial |
| Who took part, as stated | adult participants with obesity but without type 2 diabetes |
| Primary end point, as stated | The primary end point was the percent change in weight from baseline to week 72. |
| Funding, as stated | Funded by Eli Lilly |
We do not report its results here. This site sticks to label facts, and the trial is not part of either label we read.
More side by side pages
For brands that hold the same medicine, see Ozempic vs Wegovy and Mounjaro vs Zepbound. Any other pair, or three at once, is in the GLP-1 comparison chart.
Questions
What is the difference between tirzepatide and semaglutide?
Tirzepatide and semaglutide are different medicines. Tirzepatide acts on GIP and GLP-1 receptors, its labels say. Semaglutide acts on GLP-1 receptors. Their brands also have different uses and forms.
What is the difference between Mounjaro and Ozempic?
Mounjaro holds tirzepatide and Ozempic holds semaglutide. Both labels are about type 2 diabetes, and both list blood sugar control and cardiovascular risk. Only the Ozempic label adds a kidney use. The Mounjaro label also lists children from age 10 for blood sugar control.
What is the difference between Wegovy and Zepbound?
Wegovy holds semaglutide and Zepbound holds tirzepatide. Both labels list excess body weight. The Wegovy label also lists cardiovascular risk, and MASH for the shot only. The Zepbound label also lists sleep apnea. Wegovy comes as a shot and a tablet, and Zepbound as a shot.
Has tirzepatide been compared with semaglutide in a trial?
Yes. One trial compared tirzepatide with semaglutide directly. It was in adults with obesity but without type 2 diabetes. Its stated primary end point was the percent change in weight from baseline to week 72. The paper is at DOI 10.1056/NEJMoa2416394.
What is the mechanism of action of tirzepatide vs semaglutide?
Tirzepatide binds to and turns on two receptors, GIP and GLP-1, its labels say. Semaglutide binds to and turns on the GLP-1 receptor.
Sources
7 sources with read dates
- Mounjaro label on DailyMed, Eli Lilly, version 40 of 2026-08-27, read 2026-10-06
- Zepbound label on DailyMed, Eli Lilly, version 40 of 2026-08-28, read 2026-10-06
- Ozempic label on DailyMed, Novo Nordisk, version 20 of 2026-06-01, read 2026-10-06
- Wegovy label on DailyMed, Novo Nordisk, version 19 of 2026-06-18, read 2026-10-06
- Rybelsus and Ozempic tablets label on DailyMed, Novo Nordisk, version 14 of 2026-01-30, read 2026-10-06
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, Aronne LJ and others, N Engl J Med 2025, DOI 10.1056/NEJMoa2416394, abstract read 2026-10-06